Comparative effect on platelet function of a fixed-dose aspirin and clopidogrel combination versus separate formulations in patients with coronary artery disease: A phase IV, multicenter, prospective, 4-week non-inferiority trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Oh, Pyung Chun | - |
dc.contributor.author | Ahn, Taehoon | - |
dc.contributor.author | Kim, Dong Woon | - |
dc.contributor.author | Hong, Bum-Kee | - |
dc.contributor.author | Kim, Dong-Soo | - |
dc.contributor.author | Kwan, Jun | - |
dc.contributor.author | Choi, Cheol Ung | - |
dc.contributor.author | Yang, Yong-Mo | - |
dc.contributor.author | Bae, Jang Ho | - |
dc.contributor.author | Jung, Kyung Tae | - |
dc.contributor.author | Choi, Woong Gil | - |
dc.contributor.author | Jeon, Dong Woon | - |
dc.contributor.author | Cho, Deok Kyu | - |
dc.contributor.author | Pyun, Wool Bum | - |
dc.contributor.author | Cha, Kwang Soo | - |
dc.contributor.author | Cha, Tae-Joon | - |
dc.contributor.author | Chun, Kook Jin | - |
dc.contributor.author | Kim, Young Dae | - |
dc.contributor.author | Kim, Byung Soo | - |
dc.contributor.author | Kim, Doo-Il | - |
dc.contributor.author | Kim, Tae Ik | - |
dc.date.accessioned | 2021-09-04T04:16:18Z | - |
dc.date.available | 2021-09-04T04:16:18Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2016-01-01 | - |
dc.identifier.issn | 0167-5273 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/89865 | - |
dc.description.abstract | Background/objectives: The effect of aspirin and clopidogrel in a fixed-dose combination (FDC) on platelet function was compared with separate formulations in patients that had undergone percutaneous coronary intervention (PCI) with drug-eluting stent (DES). Methods: This was a phase IV, prospective, multicenter, single-arm, non-inferiority study. Patients that had taken aspirin 100 mg and clopidogrel 75 mg once daily as separate formulations for >6 months after PCI with DES were enrolled, and then switched to an aspirin/clopidogrel FDC once-daily for 4 weeks. Platelet reactivity was determined using the VerifyNow (R) P2Y12 assay at baseline (immediately prior to switching) and 4 weeks later. Results: A total of 648 patients (the full-analysis population; age, 63.6 +/- 9.0 years; male, 76.5%) finished the study, and 565 (the per-protocol population) completed without protocol violations. In the per-protocol population, the % inhibitions of P2Y12 and ARU were not significantly different between baseline and after 4 weeks of FDC treatment (29.2 +/- 20.0% to 29.0 +/- 19.9%, P= 0.708; 445.1 +/- 69.2 to 446.2 +/- 63.0, P= 0.799, respectively) and the difference in P2Y12 inhibition observed did not exceed the predetermined limit of non-inferiority (95% CI, -0.9 to 1.3). In the full-analysis population, the % inhibitions of P2Y12, PRU, and ARU were not significantly changed after 4 weeks of FDC treatment. Conclusions: This study demonstrates that the efficacy of platelet inhibition by an aspirin/clopidogrel FDC was not inferior to that of separate aspirin and clopidogrel formulations in patients that had undergone PCI with DES. (C) 2015 Elsevier Ireland Ltd. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER IRELAND LTD | - |
dc.subject | VERIFYNOW P2Y12 ASSAY | - |
dc.subject | OF-CARE ASSAY | - |
dc.subject | PROGNOSTIC-SIGNIFICANCE | - |
dc.subject | MYOCARDIAL-INFARCTION | - |
dc.subject | ANTIPLATELET THERAPY | - |
dc.subject | REACTIVITY | - |
dc.subject | INTERVENTION | - |
dc.subject | RESPONSIVENESS | - |
dc.subject | RESISTANCE | - |
dc.subject | THROMBOSIS | - |
dc.title | Comparative effect on platelet function of a fixed-dose aspirin and clopidogrel combination versus separate formulations in patients with coronary artery disease: A phase IV, multicenter, prospective, 4-week non-inferiority trial | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Cheol Ung | - |
dc.identifier.doi | 10.1016/j.ijcard.2015.09.024 | - |
dc.identifier.scopusid | 2-s2.0-84960155503 | - |
dc.identifier.wosid | 000366161500080 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF CARDIOLOGY, v.202, pp.331 - 335 | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF CARDIOLOGY | - |
dc.citation.title | INTERNATIONAL JOURNAL OF CARDIOLOGY | - |
dc.citation.volume | 202 | - |
dc.citation.startPage | 331 | - |
dc.citation.endPage | 335 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.subject.keywordPlus | VERIFYNOW P2Y12 ASSAY | - |
dc.subject.keywordPlus | OF-CARE ASSAY | - |
dc.subject.keywordPlus | PROGNOSTIC-SIGNIFICANCE | - |
dc.subject.keywordPlus | MYOCARDIAL-INFARCTION | - |
dc.subject.keywordPlus | ANTIPLATELET THERAPY | - |
dc.subject.keywordPlus | REACTIVITY | - |
dc.subject.keywordPlus | INTERVENTION | - |
dc.subject.keywordPlus | RESPONSIVENESS | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordPlus | THROMBOSIS | - |
dc.subject.keywordAuthor | Platelet function | - |
dc.subject.keywordAuthor | Fixed-dose combination | - |
dc.subject.keywordAuthor | Aspirin | - |
dc.subject.keywordAuthor | Clopidogrel | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.